Abbreviations: AIRarg, acute insulin response after the intravenous administration of arginine; AIRglc, acute insulin response after the intravenous administration of glucose; AUROC, area under the receiver operating characteristic; BETA 2, BETA-2 score; CI, confidence interval; CP/G, C-peptide/glucose ratio; CP/GCr, C-peptide/glucose creatinine ratio; DIR, daily insulin requirement; HbA1c, hemoglobin A1c; HOMA2-B%, homeostasis model assessment; IEQ, islet equivalent units; IQR, interquartile range; ITx, islet allotransplantation; LT, long term; MMTT, mixed meal tolerance test; QoL, quality of life; ROC, receiver operating characteristic; SEM, standard error of the mean; ST, short term; SUITO, secretory unit of islet transplant objects; TEF, transplant estimated function. 
Six single fasting blood sample-based indices-Secretory Unit of Islet Transplant
Objects (SUITO), Transplant Estimated Function (TEF), Homeostasis Model Assessment (HOMA)2-B%, C-peptide/glucose ratio (CP/G), C-peptide/glucose creatinine ratio (CP/GCr), and BETA-2 score-were compared against commonly used 90-minute mixed meal tolerance test (MMTT) serum glucose and beta score to assess which of them best recognizes the state of acceptable blood glucose control without insulin supplementation after islet allotransplantation (ITx). We also tested whether the indices could identify the success of ITx based on the Igls classification of beta cell graft function. We analyzed values from 47 MMTT tests in 4 patients with up to 140 months follow-up and from 54 MMTT tests in 13 patients with up to 42 months follow-up. SUITO, CP/G, HOMA2-B%, and BETA-2 correlated well with the 90-minute glucose of the MMTT and beta-score (r 0.54-0.76), whereas CP/GCr showed a modest performance (r 0.41-0.52) while TEF showed little correlation. BETA-2 and SUITO were the best identifiers and predictors of the need for insulin support, glucose intolerance, and ITx success (P < .001), while HOMA2-B% and TEF were unreliable. Single fasting blood sample SUITO and BETA-2 scores are very practical alternative tools that allow for frequent assessments of graft function.
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| INTRODUCTION
The assessment of the efficacy of beta cell replacement therapies is compound and reflects the complexity of glucose homeostasis regulation. Appropriate evaluation of beta cell graft function should include the following: average glycemic control, glycemic variability, hypoglycemic awareness, and glucose and C-peptide reaction to a standardized stimulus that triggers an insulin secretory response.
However, such comprehensive evaluations are time consuming and logistically challenging for both patients and physicians. An easily accessible graft index is highly desirable to clinically manage islet recipients, so a number of surrogate indices have been developed that utilize data obtained from only a single fasting blood sample and/or patient's history (Table 1) .
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Our objective was to compare the surrogate measures using a single fasting blood sample in order to determine which ones best serve as a simple test for predicting 90-minute glucose after the mixed meal tolerance test (MMTT) and clinical outcomes given by the beta score. We also made an attempt to see whether these could be used to objectively recognize a metabolic state of acceptable blood glucose control without the need for insulin supplementation. (Table 2) .
| PATIENTS AND METHODS
Two cohorts of patients with "brittle" type 1 diabetes mellitus, who participated in clinical studies involving ITx at the University of Chicago between March 2005 and March 2015, were analyzed. Participants provided written informed consent, and the study was approved by the University of Chicago Institutional Review Board. Our strategy for discontinuation or re-initiation of the exogenous insulin after islet transplantation was adopted from an earlier publication. 
| Mixed meal tolerance test (MMTT)
A MMTT was performed after 8 to 12 hours of fasting. Blood samples were collected for the measurement of glucose, C-peptide, and insulin concentrations at baseline and then at 0, 30, 60, 90, and 120 minutes after ingesting 6 mL/kg body weight of BOOST ® High-protein (Nestlé; 360 calories, 9 g fat, 49.5 g carbohydrate, 22.5 g protein) with a maximum of 360 mL.
| Beta score
The beta score was calculated from the patient's daily insulin requirements (DIR), hemoglobin A1c (HbA1c), fasting plasma glucose concentration, and stimulated/fasting C-peptide levels according to the method described by Ryan et al. 
| Calculation of the surrogate indices of beta cell function based on fasting blood sample
Secretory unit of islets transplant objects (SUITO) was calculated from the fasting blood glucose (mmol/L) and C-peptide (nmol/L) levels according to the method described by Takita et al.
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T A B L E 1 Brief characteristics of simple indices using a single fasting blood sample to estimate beta cell function after islet transplantation Transplant estimated function (TEF) was calculated from the DIR and HbA1c according to the method previously described.
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The homeostasis model assessment (HOMA) index of cell function is present in the literature in 2 versions: HOMA1-B% and HOMA2-B%. 10, 11 We used the HOMA2-B% method because it can be calculated relying on paired fasting plasma glucose and C-peptide instead of plasma insulin concentrations, 11 calculated with the use of a computer program (HOMA calculator) (www.dtu.ox.ac.uk/index.php?-maindoc/homa/index.php).
C-peptide/glucose ratio (CP/G) was calculated from the fasting blood glucose (mg/dL) and C-peptide (ng/mL) levels according to the method described by Faradji et al.
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C-peptide/glucose creatinine ratio (CP/GCr) was calculated from the fasting blood glucose (mg/dL), C-peptide (ng/mL) and creatinine levels according to the method described by Faradji et al:
BETA-2 score was calculated from the fasting blood glucose (mg/dL), C-peptide (ng/mL), HbA1c (%), and insulin dose (U/kg per day) as described by Forbes et al Table 2 ). Optimal or good islet function defined the success of the procedure.
| Statistical analysis
Data were tested for normality, and Pearson or Spearman rank correlation coefficients were determined, as appropriate. To account for repeated measurements within the same individual, the mixed ef- BETA − 2 score 
| RESULTS
= ( √ fasting C − peptide [nmol∕L] × (1 − insulin dose [units∕kg]) fasting plasma glucose [mmol∕L] × HbA1c [%] ) × 1000
| Relationship between reference and surrogate indices
Four indices (SUITO, CP/G, HOMA 2-B%, and BETA-2) were modestly/ well correlated with both beta score and MMTT 90-minute glucose (Table 3) 
| Surrogate indices and detection of need for insulin support and glucose intolerance
The AUROC curve analyzed for all surrogate indices showed slightly heterogeneous results, with no discriminative ability of insulin independence vs dependence for TEF (AUC=0.58, P = .52), borderline performance for HOMA2-B%, acceptable performance of SUITO, CP/G, and CP/GCr, and excellent discriminative ability for BETA-2 (AUC=0.90, P < .001) ( Table 4 , Figure 1A ). These findings mirrored the results of the correlation analyses. The AUROCs for SUITO, CP/G, CP/GCr, and BETA 2 were similar to those for the reference values, beta score, and MMTT 90-minute glucose. When we analyzed the ability of the surrogate indices to detect glucose intolerance in both groups, again all but TEF had a very good performance (Table 5 , Figure 1B ).
| Surrogate indices and detection of ITx success as defined by the Igls classification of beta cell graft function
All surrogate indices, apart from TEF and HOMA2-B%, showed excellent performance in identifying ITx success as defined by the Igls classification of beta cell graft function with AUROCs >0.8 and P < .001 (Table 6 ). The AUROCs for BETA-2, SUITO, and CP/G did not differ significantly when compared to AUROC for beta score or MMTT 90-minute glucose, but we found a significant difference in the case of TEF (poorer performance).
| Surrogate indices and predicting return to exogenous insulin therapy
In the ST group: (Table 7) . (Table 8) .
| Factors affecting the accuracy of surrogate indices
We did not find any consistent patterns when the influence of BMI and gender was analyzed.
| DISCUSSION
Despite advancements in islet procurement and immunosuppression that have increased islet transplant survival, graft function still progressively declines, and the duration of insulin independence is not permanent. Therefore, an unmet need for techniques that assess beta cell function and can be used both in a controlled experimental setting as well as in everyday clinical practice remains to be validated to allow for properly guided decision-making. It is of great importance to be able to detect early graft function decline to rescue the remaining islets from complete loss and a return to "brittle" type 1 diabetes. As TEF was designed to quantitate insulin secretion, it does not provide an integrated measure of the metabolic status of the transplant recipient, which also encompasses insulin sensitivity. 9, 10 This would account for the poor performance of TEF in our study.
CP/GCr was designed to assess islet graft dysfunction in patients with renal disease. Creatinine is the most commonly used endogenous glomerular filtration marker in clinical practice. 12 Since there are many physiologic and iatrogenic determinants of the creatinine serum level, it seems more plausible to use estimated glomerular filtration rate for the purpose of the correction. So far this index has not been validated in patients with impaired kidney function. Because all patients from both of our study populations had good kidney function, we were also unable to do so. In our population it showed modest performance, with no additional benefit.
Since HOMA2-B% cannot be applied in patients with blood glucose and C-peptide outside the set range, this limits its utility. One of the limitations of the study is that it was based on results from a single center with a particular strategy for patient clinical management as well as islet isolation and transplantation procedures. For the same reason, the number of patients included was limited. The results may not be generalizable to other transplant populations, which may have different approaches to retransplant, but we focused on insulin independence since most testing was performed in insulinindependent subjects. Other studies will likely be necessary to more accurately determine the utility of indices where function is lower.
Despite these limitations, we believe that our results have important clinical value. To our knowledge, this is the first study that undertook a robust external assessment of all currently available surrogate indices based on a single fasting blood sample using a fully independent and external validation cohort. We emphasize the need for independent validation of our findings in several populations before clinicians place great confidence in their routine use. The use of surrogate indices for autologous islet recipients is currently under investigation.
In conclusion, the 6 estimating equations showed different accuracy in identifying islets allograft dysfunction and anticipating loss of insulin independence at 1 year with reference to more logistically challenging MMTT and beta score. BETA 2, SUITO, and CP/G seem to constitute valuable, simple, and reliable methods for the evaluation of beta cell function. Therefore they should be useful in care management. 
